In this interview, David Harris (Charles River Laboratories; NC, USA) discusses the current global landscape for cell therapy, associated safety concerns and challenges, and preclinical animal models that are used to evaluate cellular therapies.
Browsing: Charles River
Discover more about how Charles River (MA, USA) employs flow cytometry to support mouse model development in this interview with Christoph Eberle and Stephen Festin.
The 2019 Bioanalysis Rising Star Award finalists have been announced! Meet Sebastien Boridy (Charles River Laboratories, Montreal, Canada) your 2019 BRSA finalist.
Charles River Laboratories have signed an agreement to acquire Citoxlab for $510 million in a deal that aims to expand their global scale and scientific service portfolio.
In this feature, we will be investigating how flow cytometry works, key advances in technology over the years and how applications for flow cytometry detection and measurement are being developed.
We talk to Christoph Eberle, Principal Scientist at Charles River Laboratories (MA, USA). Christoph explains his fascination with flow cytometry, key advantages of the technique and where he hopes the field with be in 5–10 years’ time.
Charles River (MA, USA) to expand global position with the procurement of global CRO, MPI Research (MI, USA).
The partnership with InSphero AG (Switzerland) will allow the expansion of Charles River’s (MA, USA) in vitro oncology services.
2. Given the complexity and cost of development and manufacturing, are biosimilars more affordable therapeutic options?
In this ‘Ask the Experts’ feature, the experts discuss the complexity and cost of development and whether biosimilars are more affordable therapeutic options.
In this ‘Ask the Experts’ feature we will be discussing what is required to gain approval for a biosimilar.